These findings highlight the antifibrotic potential of PDE4 inhibition, and with roflumilast already FDA approved for the treatment of COPD and additional novel agents on the horizon, our data motivate the clinical investigation of this class of drugs in patients with IPF and other fibrotic lung diseases. The gene discussed is PDE4A; the disease is idiopathic pulmonary fibrosis.